prednisolone has been researched along with Chemical and Drug Induced Liver Injury in 119 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
Chemical and Drug Induced Liver Injury: A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Imatinib mesylate is a drug that has been approved for treatment of chronic myeloid leukemia, Philadelphia-positive acute lymphoblastic leukemia, and advanced gastrointestinal stromal tumors." | 7.76 | Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors. ( Akyurek, N; Benekli, M; Buyukberber, S; Coskun, U; Demirci, U; Karakan, T; Tonyali, O; Yildiz, R, 2010) |
| "A 49-year-old-man, a healthy carrier of hepatitis B virus (HBV), received chemotherapy with a rituximab/cyclo- phosphamide/doxorubicin/vincristine/prednisolone (R-CHOP) regimen for non-Hodgkin's lymphoma." | 7.75 | [A case of drug-induced liver injury caused by entecavir for treatment of hepatitis B virus reactivation during RCHOP in a patient with non-Hodgkin lymphoma]. ( Kitada, N; Kobayashi, M; Kondo, M; Mori, A; Morita, S; Okamoto, T; Tsuji, T; Watari, M; Yoshioka, M, 2009) |
| " The patient had been treated with phenprocoumon for 5 months in order to prevent thromboembolism after two strokes assumed to be due to an open foramen ovale and an aneurysmatic atrial septum." | 7.71 | Idiosyncratic drug allergic phenprocoumon-induced hepatitis with subacute liver failure initially misdiagnosed as autoimmune hepatitis. ( Fölsch, UR; Hinrichsen, H; Klöppel, G; Lüttges, J; Schmidt, WE, 2001) |
| "Pioglitazone was effective in decreasing serum HCV RNA at day-14 (n = 10; difference of means = 205,618 IU/ml; 95% CI 26,600 to 384,600; P<0." | 6.77 | Pioglitazone decreases hepatitis C viral load in overweight, treatment naïve, genotype 4 infected-patients: a pilot study. ( Buck, M; Chojkier, M; Donohue, M; Elkhayat, H; Sabry, D, 2012) |
| "Flutamide is an antiandrogen and frequently used for the treatment of prostatic cancer." | 6.42 | [Toxic hepatitis and liver failure under therapy with flutamide]. ( Haupt, R; Lübbert, C; Ruf, BR; Wiese, M, 2004) |
| " Thalidomide is nowadays used for the treatment of several conditions including multiple myeloma (MM)." | 4.88 | Thalidomide-induced acute cholestatic hepatitis: case report and review of the literature. ( Gonçalves, R; Lopes, J; Macedo, G; Sobrinho Simões, M; Vilas-Boas, F, 2012) |
| "After initiation of prednisolone-treatment up to suspicion of drug- induced thrombocytopenia (D-ITP) and switch of the anti- Tb-regimen the general condition improved." | 4.31 | [Extrapulmonary tuberculosis: a difficult therapeutic approach]. ( Lüers, A, 2023) |
| " We conducted a preclinical trial of dissociative (vamorolone) and conventional (prednisolone) corticosteroid compounds to evaluate their effects on nociception phenotype, inflammation, and organ dysfunction in SCD mice." | 3.88 | The corticosteroid compounds prednisolone and vamorolone do not alter the nociception phenotype and exacerbate liver injury in sickle cell mice. ( Afsar, N; Albani, S; Almeida, LEF; Damsker, JM; Gordish-Dressman, H; Kamimura, S; Kleiner, DE; Pratt, D; Quezado, M; Quezado, ZMN, 2018) |
| "Imatinib mesylate is a drug that has been approved for treatment of chronic myeloid leukemia, Philadelphia-positive acute lymphoblastic leukemia, and advanced gastrointestinal stromal tumors." | 3.76 | Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors. ( Akyurek, N; Benekli, M; Buyukberber, S; Coskun, U; Demirci, U; Karakan, T; Tonyali, O; Yildiz, R, 2010) |
| "A 49-year-old-man, a healthy carrier of hepatitis B virus (HBV), received chemotherapy with a rituximab/cyclo- phosphamide/doxorubicin/vincristine/prednisolone (R-CHOP) regimen for non-Hodgkin's lymphoma." | 3.75 | [A case of drug-induced liver injury caused by entecavir for treatment of hepatitis B virus reactivation during RCHOP in a patient with non-Hodgkin lymphoma]. ( Kitada, N; Kobayashi, M; Kondo, M; Mori, A; Morita, S; Okamoto, T; Tsuji, T; Watari, M; Yoshioka, M, 2009) |
| " The co-administration of prednisolone was thus tried, and she has been able to continue imatinib mesylate administration without any liver dysfunction and finally was able to obtain a complete cytogenetic response." | 3.73 | Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management. ( Ikuta, K; Inamura, J; Jimbo, J; Kohgo, Y; Miyokawa, N; Sato, K; Shindo, M; Tokusashi, Y; Torimoto, Y, 2005) |
| " The patient had been treated with phenprocoumon for 5 months in order to prevent thromboembolism after two strokes assumed to be due to an open foramen ovale and an aneurysmatic atrial septum." | 3.71 | Idiosyncratic drug allergic phenprocoumon-induced hepatitis with subacute liver failure initially misdiagnosed as autoimmune hepatitis. ( Fölsch, UR; Hinrichsen, H; Klöppel, G; Lüttges, J; Schmidt, WE, 2001) |
| " Liver-related adverse events, laboratory data, concomitant medications, and prednisolone use were analyzed." | 3.01 | Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. ( Chand, D; Kaufmann, P; Kleyn, A; Kullak-Ublick, G; McMillan, H; Mohr, F; Montgomery, K; Sun, R; Tauscher-Wisniewski, S; Tukov, FF, 2021) |
| "Pioglitazone was effective in decreasing serum HCV RNA at day-14 (n = 10; difference of means = 205,618 IU/ml; 95% CI 26,600 to 384,600; P<0." | 2.77 | Pioglitazone decreases hepatitis C viral load in overweight, treatment naïve, genotype 4 infected-patients: a pilot study. ( Buck, M; Chojkier, M; Donohue, M; Elkhayat, H; Sabry, D, 2012) |
| "Autoimmune hepatitis is a rare cause of hepatitis in HIV-infected individuals; however, this condition has been increasingly reported over the past few years." | 2.61 | Autoimmune hepatitis in human immunodeficiency virus-infected patients: A case series and review of the literature. ( Avihingsanon, A; Chaiteerakij, R; Sanpawat, A; Treeprasertsuk, S, 2019) |
| " However, the dosing and the duration of immunosuppressive therapy have not been systematically studied in the setting of treating ipilimumab-induced irAEs." | 2.52 | Ipilimumab-induced toxicities and the gastroenterologist. ( Bye, W; Cheng, R; Cooper, A; Kench, J; McNeil, C; Shackel, N; Watson, G, 2015) |
| "Flutamide is an antiandrogen and frequently used for the treatment of prostatic cancer." | 2.42 | [Toxic hepatitis and liver failure under therapy with flutamide]. ( Haupt, R; Lübbert, C; Ruf, BR; Wiese, M, 2004) |
| "Herein, we report a patient with acute liver failure who survived with timely treatment." | 1.72 | A case of drug-induced acute liver failure caused by corticosteroids. ( Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Iritani, S; Kajiwara, A; Kawamura, Y; Kinowaki, K; Kobayashi, M; Kumada, H; Muraishi, N; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y, 2022) |
| " Our investigations excluded other possible causes for deranged LFTs and there was no improvement of same despite reduced dosing of potentially hepatotoxic medications." | 1.62 | Prednisolone: role in amoxicillin-clavulanate-induced cholestatic liver injury. ( Chigozie, R; Khan, I; Lee, MQ; O'Mara, G, 2021) |
| " Data presented are from a composite of preclinical studies, seven clinical trials, and postmarketing sources (clinical trials, n = 102 patients; postmarketing surveillance, n = 665 reported adverse event [AE] cases)." | 1.62 | Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy. ( Chand, DH; Day, JW; Finkel, RS; Kleyn, A; Mendell, JR; Mercuri, E; Reyna, SP; Strauss, KA; Tauscher-Wisniewski, S; Tukov, FF, 2021) |
| "Oral prednisolone was started at 30 mg/day, to which the patient responded well." | 1.43 | Drug-induced liver injury caused by iodine-131. ( Hong, SB; Kim, CW; Kim, JM; Le, TB; Lee, JW; Oh, SH; Park, JH; Park, JS; Shim, HI; Yoon, JW, 2016) |
| "Prednisolone treatment prevents T/NKT cell hepatitis but exacerbates hepatotoxin-induced liver injury by inhibiting macrophage- and neutrophil-mediated phagocytic and hepatic regenerative functions." | 1.40 | Opposing effects of prednisolone treatment on T/NKT cell- and hepatotoxin-mediated hepatitis in mice. ( Feng, D; Gao, B; Kwon, HJ; Park, O; Won, YS, 2014) |
| "Prednisolone is a potent anti-inflammatory glucocorticoid (GC) but chronic use is hampered by metabolic side effects." | 1.40 | Identification of gene signatures for prednisolone-induced metabolic dysfunction in collagen-induced arthritic mice. ( Bauerschmidt, S; Dokter, WH; Ellero-Simatos, S; Fleuren, WW; Toonen, EJ, 2014) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| "Ornidazole may cause drug-induced autoimmune hepatitis." | 1.37 | Ornidazole-induced autoimmune hepatitis. ( Akarca, US; Ersöz, G; Günşar, F; Karasu, Z; Tekın, F; Vardar, R; Yilmaz, F, 2011) |
| "Following repeated liver biopsy, autoimmune hepatitis was assumed and prednisolone and azathioprine were initiated." | 1.35 | [Elevated liver enzymes in rheumatoid arthritis : differential diagnostic considerations based on a case report]. ( Hartmann, U; Reuss-Borst, M; Schmitt, S, 2008) |
| "Acute toxic hepatitis was diagnosed by score of more than 3 in RUCAM criteria." | 1.33 | [Clinical experience of 48 acute toxic hepatitis patients]. ( Chae, HB; Jeon, WJ; Kim, SH; Lee, KM; Park, SM; Park, SS; Seo, JC; Youn, SJ, 2006) |
| "Liver dysfunction is a common problem in BMT recipients and it is important to determine the etiology in order to institute appropriate therapy." | 1.31 | Liver disease during the first post-transplant year in bone marrow transplantation recipients: retrospective study. ( Chung, KW; Kang, CS; Kim, BK; Kim, CC; Min, WS; Shin, WS; Sim, SI; Suh, JG; Sun, HS, 2000) |
| " Prednisolone pretreatment resulted in decreased covalent binding of the toxic metabolite in vivo and an increased urinary excretion of glutathione-derived conjugates of acetaminophen, indicating an enhanced detoxification of the reactive metabolite by glutathione." | 1.29 | Prednisolone stimulates hepatic glutathione synthesis in mice. Protection by prednisolone against acetaminophen hepatotoxicity in vivo. ( Lauterburg, BH; Schranz, C; Speck, RF, 1993) |
| "Two 19 year old patients with juvenile chronic arthritis developed liver toxicity during treatment with sulphasalazine." | 1.28 | Sulphasalazine induced hepatitis in juvenile rheumatoid arthritis. ( Caspi, D; Fuchs, D; Yaron, M, 1992) |
| "Hepatic hemorrhages are not unusual after sharp or blunt abdominal traumata." | 1.27 | [Genesis of atraumatic liver hemorrhages]. ( Weber, W, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 46 (38.66) | 18.7374 |
| 1990's | 17 (14.29) | 18.2507 |
| 2000's | 13 (10.92) | 29.6817 |
| 2010's | 33 (27.73) | 24.3611 |
| 2020's | 10 (8.40) | 2.80 |
| Authors | Studies |
|---|---|
| Fourches, D | 1 |
| Barnes, JC | 1 |
| Day, NC | 1 |
| Bradley, P | 1 |
| Reed, JZ | 1 |
| Tropsha, A | 1 |
| Morgan, RE | 2 |
| Trauner, M | 1 |
| van Staden, CJ | 2 |
| Lee, PH | 1 |
| Ramachandran, B | 1 |
| Eschenberg, M | 1 |
| Afshari, CA | 2 |
| Qualls, CW | 1 |
| Lightfoot-Dunn, R | 1 |
| Hamadeh, HK | 2 |
| Chen, M | 2 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 3 |
| Fang, H | 2 |
| Tong, W | 3 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Warner, DJ | 1 |
| Chen, H | 1 |
| Cantin, LD | 1 |
| Kenna, JG | 1 |
| Stahl, S | 1 |
| Walker, CL | 1 |
| Noeske, T | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Suzuki, A | 1 |
| Thakkar, S | 1 |
| Yu, K | 1 |
| Hu, C | 1 |
| Ueno, M | 1 |
| Takabatake, H | 1 |
| Hata, A | 1 |
| Kayahara, T | 1 |
| Morimoto, Y | 2 |
| Notohara, K | 1 |
| Mizuno, M | 1 |
| Kajiwara, A | 1 |
| Kawamura, Y | 1 |
| Kinowaki, K | 1 |
| Muraishi, N | 1 |
| Iritani, S | 1 |
| Akuta, N | 1 |
| Fujiyama, S | 1 |
| Sezaki, H | 1 |
| Hosaka, T | 1 |
| Saitoh, S | 1 |
| Kobayashi, M | 3 |
| Arase, Y | 1 |
| Ikeda, K | 1 |
| Suzuki, F | 1 |
| Suzuki, Y | 1 |
| Kumada, H | 1 |
| Lüers, A | 1 |
| Chaiteerakij, R | 1 |
| Sanpawat, A | 1 |
| Avihingsanon, A | 1 |
| Treeprasertsuk, S | 1 |
| Honda, S | 1 |
| Tsujimoto, M | 1 |
| Minegaki, T | 1 |
| Mori, T | 1 |
| Muraoka, J | 1 |
| Nishiguchi, K | 1 |
| Kulkarni, AV | 1 |
| Kumar, P | 1 |
| Talukdar, R | 1 |
| Rao, NP | 1 |
| Feldman, AG | 1 |
| Parsons, JA | 1 |
| Dutmer, CM | 1 |
| Veerapandiyan, A | 1 |
| Hafberg, E | 1 |
| Maloney, N | 1 |
| Mack, CL | 1 |
| Chand, D | 1 |
| Mohr, F | 1 |
| McMillan, H | 1 |
| Tukov, FF | 2 |
| Montgomery, K | 1 |
| Kleyn, A | 2 |
| Sun, R | 1 |
| Tauscher-Wisniewski, S | 2 |
| Kaufmann, P | 1 |
| Kullak-Ublick, G | 1 |
| Gillis, A | 1 |
| Ohri, S | 1 |
| Lee, MQ | 1 |
| Chigozie, R | 1 |
| Khan, I | 1 |
| O'Mara, G | 1 |
| Day, JW | 1 |
| Mendell, JR | 1 |
| Mercuri, E | 1 |
| Finkel, RS | 1 |
| Strauss, KA | 1 |
| Reyna, SP | 1 |
| Chand, DH | 1 |
| Borlak, J | 1 |
| van Bömmel, F | 1 |
| Berg, T | 1 |
| Akindele, AJ | 1 |
| Oludadepo, GO | 1 |
| Amagon, KI | 1 |
| Singh, D | 1 |
| Osiagwu, DD | 1 |
| Parker, M | 1 |
| McGill, NW | 1 |
| Almeida, LEF | 1 |
| Damsker, JM | 1 |
| Albani, S | 1 |
| Afsar, N | 1 |
| Kamimura, S | 1 |
| Pratt, D | 1 |
| Kleiner, DE | 1 |
| Quezado, M | 1 |
| Gordish-Dressman, H | 1 |
| Quezado, ZMN | 1 |
| Wonnaparhown, A | 1 |
| Chung, C | 1 |
| Shadix, S | 1 |
| Patel, R | 1 |
| Pandat, S | 1 |
| Chinchilla, D | 1 |
| Lindgren, B | 1 |
| Falk, J | 1 |
| Boo, YL | 1 |
| Liam, CCK | 1 |
| Toh, SG | 1 |
| Lim, SM | 1 |
| Kida, A | 1 |
| Matsuda, K | 1 |
| Matsuda, M | 1 |
| Sakai, A | 1 |
| Kwon, HJ | 1 |
| Won, YS | 1 |
| Park, O | 1 |
| Feng, D | 1 |
| Gao, B | 1 |
| Ellero-Simatos, S | 1 |
| Fleuren, WW | 1 |
| Bauerschmidt, S | 1 |
| Dokter, WH | 1 |
| Toonen, EJ | 1 |
| Cheng, R | 1 |
| Cooper, A | 1 |
| Kench, J | 1 |
| Watson, G | 1 |
| Bye, W | 1 |
| McNeil, C | 1 |
| Shackel, N | 1 |
| Vlenterie, M | 1 |
| van Erp, NP | 1 |
| van der Graaf, WT | 1 |
| Alsleben, N | 1 |
| Garcia-Prats, AJ | 1 |
| Hesseling, AC | 1 |
| Willemse, M | 1 |
| Donald, PR | 1 |
| Schaaf, HS | 1 |
| Foster, DW | 1 |
| Ecker, AH | 1 |
| Zvolensky, MJ | 1 |
| Buckner, JD | 1 |
| Däster, S | 1 |
| Eppenberger-Castori, S | 1 |
| Hirt, C | 1 |
| Soysal, SD | 1 |
| Delko, T | 1 |
| Nebiker, CA | 1 |
| Weixler, B | 1 |
| Amicarella, F | 1 |
| Iezzi, G | 1 |
| Governa, V | 1 |
| Padovan, E | 1 |
| Mele, V | 1 |
| Sconocchia, G | 1 |
| Heberer, M | 1 |
| Terracciano, L | 1 |
| Kettelhack, C | 1 |
| Oertli, D | 1 |
| Spagnoli, GC | 1 |
| von Holzen, U | 1 |
| Tornillo, L | 1 |
| Droeser, RA | 1 |
| Zhu, W | 1 |
| Germain, C | 1 |
| Sebastian, Y | 1 |
| Devi, P | 1 |
| Knockaert, S | 1 |
| Brohawn, P | 1 |
| Lehmann, K | 1 |
| Damotte, D | 1 |
| Validire, P | 1 |
| Yao, Y | 1 |
| Valge-Archer, V | 1 |
| Hammond, SA | 1 |
| Dieu-Nosjean, MC | 1 |
| Higgs, BW | 1 |
| Mendez, TL | 1 |
| De Chatterjee, A | 1 |
| Duarte, T | 1 |
| De Leon, J | 1 |
| Robles-Martinez, L | 1 |
| Das, S | 1 |
| Khurshid, SS | 1 |
| Siegel, JA | 1 |
| Kinney, KA | 1 |
| Prentoe, J | 1 |
| Verhoye, L | 1 |
| Velázquez Moctezuma, R | 1 |
| Buysschaert, C | 1 |
| Farhoudi, A | 1 |
| Wang, R | 1 |
| Alter, H | 1 |
| Meuleman, P | 1 |
| Bukh, J | 1 |
| Maejima, R | 1 |
| Uno, K | 1 |
| Iijima, K | 1 |
| Fujishima, F | 1 |
| Noguchi, T | 1 |
| Ara, N | 1 |
| Asano, N | 1 |
| Koike, T | 1 |
| Imatani, A | 1 |
| Shimosegawa, T | 1 |
| Man, S | 1 |
| Qiu, P | 1 |
| Li, J | 1 |
| Zhang, L | 1 |
| Gao, W | 1 |
| Taylor, DA | 1 |
| Perin, EC | 1 |
| Willerson, JT | 1 |
| Zierold, C | 1 |
| Resende, M | 1 |
| Carlson, M | 1 |
| Nestor, B | 1 |
| Wise, E | 1 |
| Orozco, A | 1 |
| Pepine, CJ | 1 |
| Henry, TD | 1 |
| Ellis, SG | 1 |
| Zhao, DX | 1 |
| Traverse, JH | 1 |
| Cooke, JP | 1 |
| Schutt, RC | 1 |
| Bhatnagar, A | 1 |
| Grant, MB | 1 |
| Lai, D | 1 |
| Johnstone, BH | 1 |
| Sayre, SL | 1 |
| Moyé, L | 1 |
| Ebert, RF | 1 |
| Bolli, R | 1 |
| Simari, RD | 1 |
| Cogle, CR | 1 |
| Pilleri, P | 1 |
| Joblin, C | 1 |
| Boulanger, F | 1 |
| Onaka, T | 1 |
| Morakinyo, MK | 1 |
| Chipinda, I | 1 |
| Hettick, J | 1 |
| Siegel, PD | 1 |
| Abramson, J | 1 |
| Strongin, R | 1 |
| Martincigh, BS | 1 |
| Simoyi, RH | 1 |
| Salehi, MM | 1 |
| Safarzadeh, MA | 1 |
| Sahraei, E | 1 |
| Nejad, SA | 1 |
| Izumi, H | 1 |
| Yoshiura, Y | 1 |
| Tomonaga, T | 1 |
| Oyabu, T | 1 |
| Myojo, T | 1 |
| Kawai, K | 1 |
| Yatera, K | 1 |
| Shimada, M | 1 |
| Kubo, M | 1 |
| Yamamoto, K | 1 |
| Kitajima, S | 1 |
| Kuroda, E | 1 |
| Kawaguchi, K | 1 |
| Sasaki, T | 1 |
| Windsor, LC | 1 |
| Jessell, L | 1 |
| Lassiter, T | 1 |
| Benoit, E | 1 |
| Thiessen, CE | 1 |
| Tofflemire, KL | 1 |
| Makielski, KM | 1 |
| Ben-Shlomo, G | 1 |
| Whitley, RD | 1 |
| Allbaugh, RA | 1 |
| Viu, J | 1 |
| Armengou, L | 1 |
| Ríos, J | 1 |
| Cesarini, C | 1 |
| Jose-Cunilleras, E | 1 |
| Margesin, R | 1 |
| Zhang, DC | 1 |
| Frasson, D | 1 |
| Brouchkov, A | 1 |
| Jung, WY | 1 |
| Lee, HJ | 1 |
| Jeon, CO | 1 |
| Liu, J | 1 |
| Li, F | 1 |
| Tang, XD | 1 |
| Ma, J | 1 |
| Mao, M | 1 |
| Wu, FZ | 1 |
| Bai, SJ | 1 |
| Liu, YY | 1 |
| Han, CX | 1 |
| Li, XX | 1 |
| Liu, Y | 1 |
| Song, YH | 1 |
| Wu, ZY | 1 |
| Wang, FY | 1 |
| Kang, N | 1 |
| Tanaka, KI | 1 |
| Kanazawa, I | 1 |
| Miyake, H | 1 |
| Yano, S | 1 |
| Amano, C | 1 |
| Ishikawa, N | 1 |
| Maruyama, R | 1 |
| Sugimoto, T | 1 |
| Yin, Q | 1 |
| Tao, Y | 1 |
| Zhu, X | 1 |
| Zhou, Y | 1 |
| He, X | 1 |
| Cheng, L | 1 |
| Huang, Y | 1 |
| Li, D | 1 |
| Rangachari, D | 1 |
| VanderLaan, PA | 1 |
| Le, X | 1 |
| Folch, E | 1 |
| Kent, MS | 1 |
| Gangadharan, SP | 1 |
| Majid, A | 1 |
| Haspel, RL | 1 |
| Joseph, LJ | 1 |
| Huberman, MS | 1 |
| Costa, DB | 1 |
| Moussavian, MR | 1 |
| Laschke, MW | 1 |
| Schlachtenberger, G | 1 |
| von Heesen, M | 1 |
| Wagner, M | 1 |
| Glanemann, M | 1 |
| Menger, MD | 1 |
| Kia, YH | 1 |
| Alexander, S | 1 |
| Dowling, D | 1 |
| Standish, R | 1 |
| Kim, CW | 1 |
| Park, JS | 2 |
| Oh, SH | 1 |
| Park, JH | 1 |
| Shim, HI | 1 |
| Yoon, JW | 1 |
| Hong, SB | 1 |
| Kim, JM | 1 |
| Le, TB | 1 |
| Lee, JW | 1 |
| Kondo, M | 1 |
| Kitada, N | 1 |
| Morita, S | 1 |
| Yoshioka, M | 1 |
| Tsuji, T | 1 |
| Mori, A | 1 |
| Okamoto, T | 1 |
| Watari, M | 1 |
| Tonyali, O | 1 |
| Coskun, U | 1 |
| Yildiz, R | 1 |
| Karakan, T | 1 |
| Demirci, U | 1 |
| Akyurek, N | 1 |
| Benekli, M | 1 |
| Buyukberber, S | 1 |
| Andrejic, J | 1 |
| Rojas-Balcazar, J | 1 |
| Dennis, M | 1 |
| Berkelhammer, C | 1 |
| De Moerloose, B | 1 |
| Suciu, S | 1 |
| Bertrand, Y | 1 |
| Mazingue, F | 1 |
| Robert, A | 1 |
| Uyttebroeck, A | 1 |
| Yakouben, K | 1 |
| Ferster, A | 1 |
| Margueritte, G | 1 |
| Lutz, P | 1 |
| Munzer, M | 1 |
| Sirvent, N | 1 |
| Norton, L | 1 |
| Boutard, P | 1 |
| Plantaz, D | 1 |
| Millot, F | 1 |
| Philippet, P | 1 |
| Baila, L | 1 |
| Benoit, Y | 1 |
| Otten, J | 1 |
| Sadovnikova, IV | 1 |
| Khaletskaia, OV | 1 |
| Shilenok, IG | 1 |
| Voevodkina, IF | 1 |
| Rozhdenkin, EA | 1 |
| Diallo, YL | 1 |
| Diallo, DA | 1 |
| Dembélé, AK | 1 |
| Cissoko, LN | 1 |
| Ly, M | 1 |
| Touré, BA | 1 |
| Ersöz, G | 1 |
| Vardar, R | 1 |
| Akarca, US | 1 |
| Tekın, F | 1 |
| Yilmaz, F | 1 |
| Günşar, F | 1 |
| Karasu, Z | 1 |
| Chojkier, M | 1 |
| Elkhayat, H | 1 |
| Sabry, D | 1 |
| Donohue, M | 1 |
| Buck, M | 1 |
| Coelho, J | 1 |
| Ozenne, V | 1 |
| Dray, X | 1 |
| Chaput, U | 1 |
| Marteau, P | 1 |
| Vilas-Boas, F | 1 |
| Gonçalves, R | 1 |
| Sobrinho Simões, M | 1 |
| Lopes, J | 1 |
| Macedo, G | 1 |
| Mian, M | 1 |
| Farsad, M | 1 |
| Pescosta, N | 1 |
| Casini, M | 1 |
| Cavattoni, IM | 1 |
| Deola, S | 1 |
| Cortelazzo, S | 1 |
| ABDULLAEV, NKh | 1 |
| KUROYANAGI, T | 1 |
| KURISU, A | 1 |
| SUGIYAMA, H | 1 |
| SAITO, M | 1 |
| LUPU, NG | 1 |
| POPESCU, IG | 1 |
| ZAMFIRESCU-GHEORGHIU, M | 1 |
| VELICAN, D | 1 |
| CIOBANU, F | 1 |
| Lübbert, C | 1 |
| Wiese, M | 1 |
| Haupt, R | 1 |
| Ruf, BR | 1 |
| Xia, XY | 1 |
| Peng, RX | 2 |
| Kong, R | 1 |
| Yang, ZQ | 1 |
| Chen, X | 1 |
| Yoshikane, M | 1 |
| Watanabe, H | 1 |
| Nakane, H | 1 |
| Koyama, Y | 1 |
| Anan, A | 1 |
| Suzuki, N | 1 |
| Irie, M | 1 |
| Iwata, K | 1 |
| Sohda, T | 1 |
| Sakisaka, S | 1 |
| Ikuta, K | 1 |
| Torimoto, Y | 1 |
| Jimbo, J | 1 |
| Inamura, J | 1 |
| Shindo, M | 1 |
| Sato, K | 1 |
| Tokusashi, Y | 1 |
| Miyokawa, N | 1 |
| Kohgo, Y | 1 |
| Seo, JC | 1 |
| Jeon, WJ | 1 |
| Park, SS | 1 |
| Kim, SH | 1 |
| Lee, KM | 1 |
| Chae, HB | 1 |
| Park, SM | 1 |
| Youn, SJ | 1 |
| Lewis, JJ | 1 |
| Iezzoni, JC | 1 |
| Berg, CL | 1 |
| Elefsiniotis, IS | 1 |
| Liatsos, GD | 1 |
| Stamelakis, D | 1 |
| Moulakakis, A | 1 |
| Arai, A | 1 |
| Yan, W | 1 |
| Wakabayashi, S | 1 |
| Hayashi, S | 1 |
| Inazawa, J | 1 |
| Miura, O | 1 |
| Hartmann, U | 1 |
| Schmitt, S | 1 |
| Reuss-Borst, M | 1 |
| Madhavan, TV | 1 |
| Koga, S | 1 |
| Pár, A | 1 |
| Jávor, T | 1 |
| Revillard, JP | 1 |
| Kröger, H | 1 |
| Grätz, R | 1 |
| Museteanu, C | 1 |
| Haase, J | 1 |
| Gandolfi, R | 1 |
| Culbertson, R | 1 |
| Kuz'menko, SA | 1 |
| Lokaĭ, AI | 1 |
| Smorshchok, SA | 1 |
| Volkov, KS | 1 |
| Kawasaki, H | 1 |
| Murawaki, Y | 1 |
| Bessho, F | 1 |
| Kinumaki, H | 1 |
| Yokota, S | 1 |
| Hayashi, Y | 1 |
| Kamoshita, S | 1 |
| Speck, RF | 1 |
| Schranz, C | 1 |
| Lauterburg, BH | 1 |
| Wu, DF | 1 |
| Wang, H | 1 |
| Kamiyama, T | 1 |
| Nouchi, T | 1 |
| Kojima, S | 1 |
| Murata, N | 1 |
| Ikeda, T | 1 |
| Sato, C | 1 |
| Gerolami, R | 1 |
| Mambrini, P | 1 |
| Barthet, M | 1 |
| Jean-Pastor, MJ | 1 |
| Salducci, J | 1 |
| Grimaud, JC | 1 |
| Syakalima, M | 1 |
| Takiguchi, M | 1 |
| Yasuda, J | 1 |
| Morita, Y | 1 |
| Hashimoto, A | 1 |
| Pittau, S | 1 |
| Morelli, S | 1 |
| Venturini, E | 1 |
| Boldorini, R | 1 |
| Sartori, M | 1 |
| Nanki, T | 1 |
| Koike, R | 1 |
| Miyasaka, N | 1 |
| Kim, BK | 1 |
| Chung, KW | 1 |
| Sun, HS | 1 |
| Suh, JG | 1 |
| Min, WS | 1 |
| Kang, CS | 1 |
| Sim, SI | 1 |
| Shin, WS | 1 |
| Kim, CC | 1 |
| Schneider, AR | 1 |
| Hartmann, D | 1 |
| Arnold, JC | 1 |
| Bohrer, MH | 1 |
| Riemann, JF | 1 |
| Hinrichsen, H | 1 |
| Lüttges, J | 1 |
| Klöppel, G | 1 |
| Fölsch, UR | 1 |
| Schmidt, WE | 1 |
| Platt, D | 3 |
| Leinweber, B | 1 |
| Förster, L | 3 |
| Förster, K | 3 |
| Bank, JI | 1 |
| Lykkebo, D | 1 |
| Hägerstrand, I | 1 |
| Stramentinoli, G | 1 |
| Gualano, M | 1 |
| Ideo, G | 1 |
| Sherlock, S | 3 |
| Pickering, RW | 1 |
| Lynn James, GW | 1 |
| Parker, FL | 1 |
| Ding, A | 1 |
| Wang, S | 1 |
| Kong, L | 1 |
| Li, X | 1 |
| Vyse, T | 1 |
| So, AK | 1 |
| Caspi, D | 1 |
| Fuchs, D | 1 |
| Yaron, M | 1 |
| Brooks, H | 1 |
| Taylor, HG | 1 |
| Nichol, FE | 1 |
| Soh, LT | 1 |
| Ang, PT | 1 |
| Sng, I | 1 |
| Chua, EJ | 1 |
| Ong, YW | 1 |
| De Leeuw, P | 1 |
| Lefebvre, C | 1 |
| Tomasi, JP | 1 |
| Rahier, J | 1 |
| Geubel, A | 1 |
| Daibo, A | 1 |
| Yoshida, Y | 1 |
| Kitazawa, S | 1 |
| Kosaka, Y | 1 |
| Bando, T | 1 |
| Sudo, M | 1 |
| Min, KS | 1 |
| Mukai, S | 1 |
| Ohta, M | 1 |
| Onosaka, S | 1 |
| Tanaka, K | 1 |
| Onyezili, FN | 1 |
| Esquivel, CO | 1 |
| Jaffe, R | 1 |
| Gordon, RD | 1 |
| Iwatsuki, S | 1 |
| Shaw, BW | 1 |
| Starzl, TE | 1 |
| Nagai, H | 1 |
| Yakuo, I | 1 |
| Yamada, H | 1 |
| Shimazawa, T | 1 |
| Koda, A | 1 |
| Niu, K | 1 |
| Asano, K | 1 |
| Shimizu, T | 1 |
| Kasahara, M | 1 |
| Buti, M | 1 |
| Esteban, R | 1 |
| Esteban, JI | 1 |
| Gonzalez, A | 1 |
| Guardia, J | 1 |
| Yamanaka, M | 1 |
| Sano, N | 1 |
| Itokazu, K | 1 |
| Yokote, M | 1 |
| Torii, M | 1 |
| Miyake, K | 1 |
| Sasaki, J | 1 |
| Hara, F | 1 |
| Motooka, T | 1 |
| Naito, S | 1 |
| Arakawa, K | 1 |
| Weber, W | 1 |
| Otsuka, M | 1 |
| Fujimura, M | 1 |
| Koshino, T | 1 |
| Ueda, M | 1 |
| Otake, S | 1 |
| Funada, H | 1 |
| Harada, M | 1 |
| Nakamura, S | 1 |
| Matsuda, T | 1 |
| Scheuer, PJ | 1 |
| Summerfield, JA | 1 |
| Lal, S | 1 |
| Fung, WP | 1 |
| Mattson, K | 1 |
| Lesesne, HR | 1 |
| Fallon, HJ | 2 |
| Chakrabarti, AK | 1 |
| Lloyd, GH | 1 |
| Jakó, J | 1 |
| Nagy, P | 1 |
| Helman, RA | 1 |
| Temko, MH | 1 |
| Nye, SW | 1 |
| Juchum, W | 1 |
| Selye, H | 1 |
| Szabo, S | 1 |
| Tuchweber, B | 1 |
| Lefebvre, F | 1 |
| Ambre, JJ | 1 |
| Fischer, LJ | 1 |
| From, E | 1 |
| Simonsen, EE | 1 |
| Shamov, IA | 1 |
| Pidémskiĭ, EL | 1 |
| Cherednichenko, RP | 1 |
| Chukichev, EM | 1 |
| Swick, RW | 1 |
| Tollaksen, SL | 1 |
| Nance, SL | 1 |
| Thomson, JF | 1 |
| Bhagwat, AG | 2 |
| Diaz-Rubio Garcia, M | 1 |
| Reynolds, TB | 1 |
| Edmonson, HA | 1 |
| Ross, RC | 1 |
| Fritsch, H | 1 |
| Kaess, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2[NCT03505099] | Phase 3 | 30 participants (Actual) | Interventional | 2018-04-02 | Completed | ||
| Phase I Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 Delivering AVXS-101[NCT02122952] | Phase 1 | 15 participants (Actual) | Interventional | 2014-05-05 | Completed | ||
| A Long-term Follow-up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving AVXS-101[NCT04042025] | Phase 3 | 85 participants (Actual) | Interventional | 2020-02-10 | Active, not recruiting | ||
| A Long Term Follow up Safety Study of Patients in the AVXS-101-CL-101 Gene Replacement Therapy Clinical Trial for Spinal Muscular Atrophy Type 1 Delivering AVXS 101[NCT03421977] | 13 participants (Actual) | Observational | 2017-09-21 | Active, not recruiting | |||
| Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion[NCT03461289] | Phase 3 | 33 participants (Actual) | Interventional | 2018-08-16 | Completed | ||
| Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion[NCT03837184] | Phase 3 | 2 participants (Actual) | Interventional | 2019-05-31 | Completed | ||
| Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion[NCT03306277] | Phase 3 | 22 participants (Actual) | Interventional | 2017-10-24 | Completed | ||
| A Phase II Open-Label, Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD)[NCT05185622] | Phase 2 | 54 participants (Anticipated) | Interventional | 2022-03-21 | Recruiting | ||
| A Phase II Pilot Trial of Vamorolone vs. Placebo for the Treatment of Becker Muscular Dystrophy[NCT05166109] | Phase 2 | 39 participants (Anticipated) | Interventional | 2022-07-07 | Recruiting | ||
| The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenanc[NCT00003728] | Phase 3 | 1,500 participants (Anticipated) | Interventional | 1998-12-31 | Active, not recruiting | ||
| A Randomized, Partially Blinded, Pilot Study of the Effects of Pioglitazone on HCV RNA in Overweight Subjects With Chronic HCV Genotypes 1 or 4 Infection.[NCT01157975] | Phase 2 | 0 participants (Actual) | Interventional | 2008-10-31 | Withdrawn (stopped due to Study was completed in another site) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Event-free survival at 14 months of age was defined as the number of participants who did not die, did not require permanent ventilation and did not withdraw from the study by 14 months of age. (NCT03505099)
Timeframe: From Day 1 up to 14 months of age
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1: Bi-allelic Deletions of SMN1 and 2 Copies of SMN2 | 14 |
Defined by the Bayley Scales of Infant and Toddler Development (BSID) Gross Motor (GM) subtest performance criteria number 26, confirmed by video recording, as a participant who sits for at least 30 seconds without assistance from another person or object. The participant was allowed to use their upper extremities. (NCT03505099)
Timeframe: From Day 1 up to 18 months of age visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1: Bi-allelic Deletions of SMN1 and 2 Copies of SMN2 | 14 |
"The ability to maintain weight at or above the third percentile without the need for non-oral or mechanical feeding support was defined by meeting the following criteria at each visit up to 18 months of age:~Did not receive nutrition through mechanical support (i.e., feeding tube)~Maintained weight (≥ third percentile for age and sex as defined by World Health Organization [WHO] guidelines) consistent with the participant's age at the assessment." (NCT03505099)
Timeframe: From Day 1 up to 18 months of age
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1: Bi-allelic Deletions of SMN1 and 2 Copies of SMN2 | 13 |
Defined by the BSID GM subtest performance criteria number 40, confirmed by video recording, as a participant who stands alone for at least 3 seconds unsupported. (NCT03505099)
Timeframe: From Day 1 up to 24 months of age visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 2: Bi-allelic Deletions of SMN1 and 3 Copies of SMN2 | 15 |
Defined by the BSID GM subtest performance criteria number 43, confirmed by video recording, as a participant who takes 5 coordinated independent steps. (NCT03505099)
Timeframe: From Day 1 up to 24 months of age visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 2: Bi-allelic Deletions of SMN1 and 3 Copies of SMN2 | 14 |
(NCT02122952)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 | 1 |
| Cohort 2 | 3 |
Permanent ventilation was defined as the requirement of ≥ 16-hour respiratory assistance, including non-invasive ventilatory support, per day continuously for ≥ 2 weeks in the absence of an acute reversible illness, excluding perioperative ventilation. (NCT02122952)
Timeframe: Up to 13.6 months of age
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 | 0 |
| Cohort 2 | 0 |
Improvement in motor function was determined by achievement of developmental milestones, specifically achievement of ability to sit unassisted for at least 30 seconds, determined by physical therapist and confirmed by an independent central video reviewer. Achievement of functional independent sitting was defined as the ability to maintain a sitting position independently for at least 30 seconds as confirmed per video evaluation by an expert central reviewer based on videos taken either at scheduled visits or provided by the parent/legal guardian. (NCT02122952)
Timeframe: 24 months post-dose
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 | 0 |
| Cohort 2 | 9 |
Score ranges from 0 to 64, where 64 is the maximum possible score. A higher score is indicative of higher/better motor function. CHOP-INTEND assessments were discontinued once patients achieved higher functioning status, so the number of available data points decreased over time. (NCT02122952)
Timeframe: Baseline to 24 months post-dose
| Intervention | Percentage Change (Mean) |
|---|---|
| Cohort 2 | 30.7 |
Event-free survival at 14 months of age was defined as the number of participants who did not die, did not require permanent ventilation and did not withdraw from the study by 14 months of age. (NCT03461289)
Timeframe: Up to 14 months of age
| Intervention | Participants (Count of Participants) |
|---|---|
| Onasemnogene Abeparvovec-xioi | 31 |
Independent sitting is defined by the World Health Organization Multicentre Growth Reference Study, confirmed by video recording, as a participant who sits up straight with head erect for at least 10 seconds; participant does not use arms or hands to balance body or support position. (NCT03461289)
Timeframe: From Day 1 up to 18 Months of Age Visit (Up to a Maximum of Approximately 17 Months)
| Intervention | Participants (Count of Participants) |
|---|---|
| Onasemnogene Abeparvovec-xioi | 14 |
Event-free survival at 14 months of age was defined as the number of participants who did not die, did not require permanent ventilation and did not withdraw from the study by 14 months of age. (NCT03837184)
Timeframe: From Baseline up to 14 Months of Age
| Intervention | Participants (Count of Participants) |
|---|---|
| AVXS-101 | 2 |
Independent sitting is defined by the World Health Organization Multicentre Growth Reference Study, confirmed by video recording, as a participant who sits up straight unsupported for at least 10 seconds. (NCT03837184)
Timeframe: From Baseline up to 18 Months of Age Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| AVXS-101 | 1 |
"Ability to thrive is defined as achieving all of the following at 18 months of age:~does not receive nutrition through mechanical support or other non-oral method~ability to tolerate thin liquids as demonstrated through a formal swallowing test~maintains weight~This is a co-secondary endpoint. The two co-secondary endpoints were assessed in sequence: The endpoint of ability to thrive was assessed first and, only when this assessment met statistical significance was the endpoint of ventilatory support independence assessed." (NCT03306277)
Timeframe: 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Onasemnogene Abeparvovec-xioi | 9 |
"Independent sitting is defined as sitting up straight with head erect for at least 30 seconds.~This endpoint is a co-primary endpoint. The two co-primary efficacy endpoints were assessed in sequence: The endpoint of functional independent sitting was assessed first and, only when this assessment met statistical significance, was the endpoint of event-free survival assessed." (NCT03306277)
Timeframe: Up to 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Onasemnogene Abeparvovec-xioi | 13 |
"Survival is defined by the avoidance of combined endpoint of either death or permanent ventilation, which is defined by tracheostomy or by the requirement of ≥ 16 hours of respiratory assistance per day for ≥ 14 consecutive days in the absence of an acute reversible illness, excluding perioperative ventilation. Permanent ventilation is considered a surrogate for death. An acute reversible illness is defined as any condition other than SMA that results in increased medical intervention.~The endpoint is a co-primary endpoint. The two co-primary efficacy endpoints were assessed in sequence: The endpoint of functional independent sitting was assessed first and, only when this assessment met statistical significance was the survival endpoint assessed." (NCT03306277)
Timeframe: 14 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Onasemnogene Abeparvovec-xioi | 20 |
"Ventilatory support independence is defined as requiring no daily ventilator support/usage at 18 months of age, excluding acute reversible illness and perioperative ventilation, through assessment of actual usage data captured from the device (Phillips Trilogy BiPAP device). This endpoint is derived solely from the Phillips Trilogy BiPAP device.~This is a co-secondary endpoint. The two co-secondary endpoints were assessed in sequence: The endpoint of ability to thrive was assessed first and, only when this assessment met statistical significance was the endpoint of ventilatory support independence assessed." (NCT03306277)
Timeframe: Up to 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Onasemnogene Abeparvovec-xioi | 18 |
12 reviews available for prednisolone and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Pr | 2016 |
Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review.
Topics: Adrenal Cortex Hormones; Aged; Chemical and Drug Induced Liver Injury; Drug Tapering; Humans; Immune | 2022 |
Autoimmune hepatitis in human immunodeficiency virus-infected patients: A case series and review of the literature.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Antibodies, Antinuclear; Aspartate Aminotransferases; | 2019 |
Ipilimumab-induced toxicities and the gastroenterologist.
Topics: Antibodies, Monoclonal; Azathioprine; Calcineurin Inhibitors; Chemical and Drug Induced Liver Injury | 2015 |
Thalidomide-induced acute cholestatic hepatitis: case report and review of the literature.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemical and Drug Induc | 2012 |
[Toxic hepatitis and liver failure under therapy with flutamide].
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Hormonal; Biopsy, Needle; Chemical and Drug I | 2004 |
Successful imatinib treatment of cardiac involvement of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia followed by severe hepatotoxicity.
Topics: Adult; Antineoplastic Agents; Benzamides; Biopsy; Chemical and Drug Induced Liver Injury; Chromosome | 2007 |
[Various problems in therapy and prognosis of drug-induced liver diseases].
Topics: Chemical and Drug Induced Liver Injury; Diet, Fat-Restricted; Drug-Related Side Effects and Adverse | 1995 |
Autoimmune hepatitis triggered by administration of an herbal medicine.
Topics: Autoimmune Diseases; Chemical and Drug Induced Liver Injury; Drug Combinations; Drugs, Chinese Herba | 1997 |
[Toxic hepatitis induced by steroids].
Topics: Anabolic Agents; Androgens; Animals; Bile Acids and Salts; Chemical and Drug Induced Liver Injury; C | 1985 |
Treatment of liver disease with corticosteroids.
Topics: Adrenal Cortex Hormones; Alcoholism; Azathioprine; Chemical and Drug Induced Liver Injury; Glucocort | 1973 |
Chronic hepatitis.
Topics: Adult; Animals; Autoimmune Diseases; Azathioprine; Chemical and Drug Induced Liver Injury; Child; Ch | 1974 |
4 trials available for prednisolone and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Bilirubin; Biological Products; Chemical and Drug | 2021 |
Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized phase 3 trial 58951.
Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced L | 2010 |
Pioglitazone decreases hepatitis C viral load in overweight, treatment naïve, genotype 4 infected-patients: a pilot study.
Topics: Adult; Antiviral Agents; Blood Glucose; Chemical and Drug Induced Liver Injury; Cytokines; Female; G | 2012 |
Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy.
Topics: Adult; Aged; Alanine Transaminase; Alcoholism; Alkaline Phosphatase; Aspartate Aminotransferases; Bi | 1971 |
103 other studies available for prednisolone and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLI | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
A case of drug-induced acute liver failure caused by corticosteroids.
Topics: Adrenal Cortex Hormones; Alanine Transaminase; Antibodies, Antinuclear; Aspartate Aminotransferases; | 2022 |
[Extrapulmonary tuberculosis: a difficult therapeutic approach].
Topics: Adult; Chemical and Drug Induced Liver Injury; Fever; Humans; Male; Prednisolone; Thrombocytopenia; | 2023 |
A case of idiosyncratic liver injury after oxaliplatin-induced thrombocytopenia.
Topics: Anaphylaxis; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; | 2020 |
Steroids as rescue therapy for vitamin A-induced acute liver failure.
Topics: Adult; Antioxidants; Chemical and Drug Induced Liver Injury; Diagnosis, Differential; Glucocorticoid | 2020 |
Subacute Liver Failure Following Gene Replacement Therapy for Spinal Muscular Atrophy Type 1.
Topics: Chemical and Drug Induced Liver Injury; Female; Genetic Therapy; Glucocorticoids; Humans; Infant; Ma | 2020 |
17-year-old girl • abdominal pain • lower-leg itching • dark urine and yellow eyes • Dx?
Topics: Abdominal Pain; Acne Vulgaris; Adolescent; Analgesics; Antipruritics; Chemical and Drug Induced Live | 2020 |
Prednisolone: role in amoxicillin-clavulanate-induced cholestatic liver injury.
Topics: Aged; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Chemical and Drug Induced Liver In | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Topics: Animals; Biological Products; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gene | 2021 |
N-acetylcysteine and prednisolone treatment improved serum biochemistries in suspected flupirtine cases of severe idiosyncratic liver injury.
Topics: Acetylcysteine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aminopyridines; Analgesics; An | 2018 |
Protective effect of carvedilol alone and coadministered with diltiazem and prednisolone on doxorubicin and 5-fluorouracil-induced hepatotoxicity and nephrotoxicity in rats.
Topics: Acute Kidney Injury; Animals; Antibiotics, Antineoplastic; Carbazoles; Carvedilol; Chemical and Drug | 2018 |
Minocycline-associated polyarteritis nodosa and self-limiting hepatitis: a reminder of a potentially re-emerging culprit in drug-induced autoimmune syndromes.
Topics: Adult; Anti-Bacterial Agents; Chemical and Drug Induced Liver Injury; Glucocorticoids; Humans; Male; | 2018 |
The corticosteroid compounds prednisolone and vamorolone do not alter the nociception phenotype and exacerbate liver injury in sickle cell mice.
Topics: Anemia, Sickle Cell; Animals; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Fema | 2018 |
The corticosteroid compounds prednisolone and vamorolone do not alter the nociception phenotype and exacerbate liver injury in sickle cell mice.
Topics: Anemia, Sickle Cell; Animals; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Fema | 2018 |
The corticosteroid compounds prednisolone and vamorolone do not alter the nociception phenotype and exacerbate liver injury in sickle cell mice.
Topics: Anemia, Sickle Cell; Animals; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Fema | 2018 |
The corticosteroid compounds prednisolone and vamorolone do not alter the nociception phenotype and exacerbate liver injury in sickle cell mice.
Topics: Anemia, Sickle Cell; Animals; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Fema | 2018 |
Liver injury, rash, and encephalopathy in a 23-year-old Asian man prescribed dapsone.
Topics: Adult; Anti-Infective Agents; Antiviral Agents; Brain Diseases; Chemical and Drug Induced Liver Inju | 2019 |
Rechallenge of ponatinib in chronic myeloid leukaemia after hepatotoxicity.
Topics: Adult; Chemical and Drug Induced Liver Injury; Humans; Imidazoles; Leukemia, Myelogenous, Chronic, B | 2019 |
Hepatobiliary and Pancreatic: Biliary injury related to checkpoint inhibitor "pembrolizumab".
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; B | 2019 |
Opposing effects of prednisolone treatment on T/NKT cell- and hepatotoxin-mediated hepatitis in mice.
Topics: Animals; Carbon Tetrachloride; Chemical and Drug Induced Liver Injury; Concanavalin A; Disease Model | 2014 |
Identification of gene signatures for prednisolone-induced metabolic dysfunction in collagen-induced arthritic mice.
Topics: Animals; Anti-Inflammatory Agents; Arthritis; Chemical and Drug Induced Liver Injury; Collagen Disea | 2014 |
Promising management of pazopanib-induced liver toxicity.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Female; H | 2015 |
Successful Treatment of a Child With Extensively Drug-Resistant Tuberculous Meningitis.
Topics: Anti-Inflammatory Agents; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child, Pres | 2015 |
Topics: Acid-Base Imbalance; Acidosis, Renal Tubular; Aged; Air Pollution, Indoor; Amino Acid Substitution; | 2015 |
A case of steroid-responsive valerian-associated hepatitis.
Topics: Chemical and Drug Induced Liver Injury; Humans; Male; Middle Aged; Plant Preparations; Prednisolone; | 2016 |
Drug-induced liver injury caused by iodine-131.
Topics: Abdomen; Chemical and Drug Induced Liver Injury; Female; Humans; Iodine Radioisotopes; Lymph Nodes; | 2016 |
[A case of drug-induced liver injury caused by entecavir for treatment of hepatitis B virus reactivation during RCHOP in a patient with non-Hodgkin lymphoma].
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineo | 2009 |
Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors.
Topics: Acute Disease; Anti-Inflammatory Agents; Antineoplastic Agents; Benzamides; Chemical and Drug Induce | 2010 |
Azathioprine-induced hypersensitivity hepatitis: tolerance to 6-mercaptopurine.
Topics: Acute Disease; Azathioprine; Chemical and Drug Induced Liver Injury; Colitis, Ulcerative; Drug Hyper | 2010 |
[Acute toxic hepatitis at mushroom poisoning of the young child].
Topics: Chemical and Drug Induced Liver Injury; Diagnosis, Differential; Gastroenteritis; Humans; Infant; Ma | 2010 |
[A case of the association of acute lymphoblastic lymphoma with active tuberculosis in the child: a Malian case].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Antitubercular Ag | 2010 |
Ornidazole-induced autoimmune hepatitis.
Topics: Adult; Azathioprine; Biopsy; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Fema | 2011 |
Case of prednisolone-induced hepatitis in a patient with ulcerative colitis.
Topics: Chemical and Drug Induced Liver Injury; Colitis, Ulcerative; Female; Glucocorticoids; Humans; Middle | 2013 |
Bendamustine salvage for the treatment of relapsed Hodgkin's lymphoma after allogeneic bone marrow transplantation.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined C | 2013 |
[CERTAIN LIPID METABOLISM INDICES AND THEIR CHANGES UNDER THE INFLUENCE OF PREDNISOLONE IN EXPERIMENTAL HEPATITIS].
Topics: Carbon Tetrachloride Poisoning; Chemical and Drug Induced Liver Injury; Hepatitis; Lipid Metabolism; | 1964 |
[Studies on experimental allergic hepatitis. 2. Effect of prednisolone and glycyrrhizin on experimental allergic hepatitis].
Topics: Antioxidants; Chemical and Drug Induced Liver Injury; Glycyrrhiza; Glycyrrhizic Acid; Hepatitis; Hep | 1962 |
[Therapeutic investigations in experimental toxic chronic hepatitis].
Topics: Chemical and Drug Induced Liver Injury; Corrinoids; Cytochromes; Hepatitis; Hepatitis, Chronic; Pred | 1961 |
[Effects of Angelica sinensis polysaccharides on hepatic drug metabolism enzymes activities in mice].
Topics: Aminopyrine N-Demethylase; Angelica sinensis; Aniline Hydroxylase; Animals; Chemical and Drug Induce | 2003 |
[A case of rapid onset autoimmune hepatitis resembling drug-induced liver disease in a Japanese young woman].
Topics: Adult; Anti-Inflammatory Agents; Biopsy; Chemical and Drug Induced Liver Injury; Female; Hepatitis, | 2004 |
Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management.
Topics: Antineoplastic Agents; Benzamides; Biopsy; Chemical and Drug Induced Liver Injury; Enzyme Inhibitors | 2005 |
[Clinical experience of 48 acute toxic hepatitis patients].
Topics: Acute Disease; Adult; Chemical and Drug Induced Liver Injury; Female; Glucocorticoids; Humans; Jaund | 2006 |
Methylphenidate-induced autoimmune hepatitis.
Topics: Alanine Transaminase; Anti-Inflammatory Agents; Aspartate Aminotransferases; Bilirubin; Central Nerv | 2007 |
Case report: mixed cholestatic/hepatocellular liver injury induced by the herbicide quizalofop-p-ethyl.
Topics: Aged; Anti-Inflammatory Agents; Bile Acids and Salts; Chemical and Drug Induced Liver Injury; Choles | 2007 |
[Elevated liver enzymes in rheumatoid arthritis : differential diagnostic considerations based on a case report].
Topics: Adalimumab; Adolescent; Alanine Transaminase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humani | 2008 |
Effect of prednisolone on liver damage in rats induced by aflatoxin.
Topics: Aflatoxins; Animals; Chemical and Drug Induced Liver Injury; Dietary Proteins; Liver Diseases; Predn | 1967 |
[Lipoprotein biosynthesis in the liver in various conditions].
Topics: Animals; Carbon Isotopes; Carbon Tetrachloride; Chemical and Drug Induced Liver Injury; In Vitro Tec | 1967 |
Alternatives in hepatoprotection: cytoprotection--influences on mono-oxidase system--free radical scavengers (a review).
Topics: Animals; Antioxidants; Catechin; Chemical and Drug Induced Liver Injury; Enzyme Induction; Free Radi | 1984 |
Significance of beta 2-microglobulin in liver diseases.
Topics: beta 2-Microglobulin; Beta-Globulins; Chemical and Drug Induced Liver Injury; Chronic Disease; Hepat | 1980 |
The influence of nicotinamide, tryptophan, and methionine upon galactosamine-induced effects in the liver.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; | 1981 |
Corticosteroid-induced death in an opossum.
Topics: Animals; Animals, Zoo; Chemical and Drug Induced Liver Injury; Dermatitis, Contact; Female; Liver; L | 1983 |
[Effect of lipoic acid, cocarboxylase and prednisolone on hepatocyte ultrastructure in toxic hepatitis].
Topics: Animals; Chemical and Drug Induced Liver Injury; Liver; Male; Mushroom Poisoning; Prednisolone; Rats | 1982 |
Liver function studies in children with acute lymphocytic leukemia after cessation of therapy.
Topics: Adolescent; Adult; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Asparaginas | 1994 |
Prednisolone stimulates hepatic glutathione synthesis in mice. Protection by prednisolone against acetaminophen hepatotoxicity in vivo.
Topics: Acetaminophen; Animals; Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme System; Glut | 1993 |
[Sodium ferulate alleviates prednisolone induced liver toxicity in mice].
Topics: Alanine Transaminase; Animals; Cell Membrane; Chemical and Drug Induced Liver Injury; Coumaric Acids | 1995 |
[Acute hepatitis caused by Solupred in a patient with Crohn disease].
Topics: Acute Disease; Adult; Chemical and Drug Induced Liver Injury; Crohn Disease; Female; Glucocorticoids | 1997 |
Comparison of attenuation and liver-kidney contrast of liver ultrasonographs with histology and biochemistry in dogs with experimentally induced steroid hepatopathy.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Anti-Inflammatory Agents; Chemical and Drug Ind | 1998 |
[Post-infantile giant cell hepatitis. Clinical and histological response to immunosuppressive therapy].
Topics: Adult; Azathioprine; Chemical and Drug Induced Liver Injury; Fibrinolytic Agents; Glucocorticoids; H | 1998 |
Subacute severe steatohepatitis during prednisolone therapy for systemic lupus erythematosis.
Topics: Acute Disease; Alanine Transaminase; Anti-Inflammatory Agents; Aspartate Aminotransferases; Chemical | 1999 |
Liver disease during the first post-transplant year in bone marrow transplantation recipients: retrospective study.
Topics: Adult; Antineoplastic Agents; Bone Marrow Transplantation; Chemical and Drug Induced Liver Injury; F | 2000 |
[Phenprocoumon-induced necrotizing hepatitis].
Topics: Anti-Inflammatory Agents; Anticoagulants; Biopsy; Chemical and Drug Induced Liver Injury; Clinical E | 2001 |
Idiosyncratic drug allergic phenprocoumon-induced hepatitis with subacute liver failure initially misdiagnosed as autoimmune hepatitis.
Topics: Anti-Inflammatory Agents; Anticoagulants; Biopsy; Chemical and Drug Induced Liver Injury; Diagnostic | 2001 |
[The effect of prednisolone on the development of the galactosamine hepatitis of young and old rats (author's transl)].
Topics: Age Factors; Alanine Transaminase; Animals; Aspartate Aminotransferases; Chemical and Drug Induced L | 1976 |
[Incorporation of 14-C-Glycine during galactosamine hepatitis of young and old rats (author's transl)a*].
Topics: Age Factors; Animals; Chemical and Drug Induced Liver Injury; Female; Galactosamine; Glycine; Liver; | 1976 |
Age dependent kinetic studies of cytoplasmic and lysosomal enzymes of the normal and D-galactosamine injured rat liver.
Topics: Acetylglucosaminidase; Age Factors; Alanine Transaminase; Animals; Aspartate Aminotransferases; Cath | 1978 |
Peliosis hepatis in a child.
Topics: Chemical and Drug Induced Liver Injury; Child, Preschool; Cysts; Fanconi Anemia; Humans; Liver; Live | 1978 |
Protective role of S-adenosyl-L-methionine on liver injury induced by D-galactosamine in rats.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; | 1978 |
Diagnosis and treatment of chronic active hepatitis.
Topics: Adolescent; Adult; Azathioprine; Chemical and Drug Induced Liver Injury; Chronic Disease; Female; He | 1977 |
Inhibition, by drugs, of galactosamine induced hepatitis in the rat.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Azathioprine; Chemical and Drug Induced | 1975 |
[Pharmacological studies on erzhi pills].
Topics: Animals; Carbon; Chemical and Drug Induced Liver Injury; Drug Combinations; Drug Synergism; Drugs, C | 1992 |
Sulphasalazine induced autoimmune syndrome.
Topics: Adult; Arthritis, Rheumatoid; Autoimmune Diseases; Chemical and Drug Induced Liver Injury; Drug Erup | 1992 |
Sulphasalazine induced hepatitis in juvenile rheumatoid arthritis.
Topics: Adolescent; Adult; Alkaline Phosphatase; Arthritis, Juvenile; Chemical and Drug Induced Liver Injury | 1992 |
The three week sulphasalazine syndrome.
Topics: Arthritis, Rheumatoid; Chemical and Drug Induced Liver Injury; Humans; Male; Middle Aged; Prednisolo | 1992 |
Fulminant hepatic failure in non-Hodgkin lymphoma patients treated with chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chemical and Drug Induced Li | 1992 |
[Severe hepatitis with encephalopathy induced by acetylsalicylic acid in a case of lupus erythematosus disseminatus].
Topics: Aspirin; Chemical and Drug Induced Liver Injury; Female; Hepatic Encephalopathy; Humans; Lupus Eryth | 1992 |
[A case of pneumonitis and hepatic injury caused by a herbal drug (sho-saiko-to)].
Topics: Alveolitis, Extrinsic Allergic; Chemical and Drug Induced Liver Injury; Drugs, Chinese Herbal; Human | 1992 |
Glucocorticoid inhibition of inflammation-induced metallothionein synthesis in mouse liver.
Topics: Animals; Chemical and Drug Induced Liver Injury; Dexamethasone; Drug Interactions; Endotoxins; Fibri | 1992 |
On two paradoxical side-effects of prednisolone in rats, ribosomal RNA biosyntheses, and a mechanism of action.
Topics: Animals; Body Weight; Chemical and Drug Induced Liver Injury; Liver; Liver Diseases; Male; Muscle Pr | 1986 |
Liver rejection and its differentiation from other causes of graft dysfunction.
Topics: Bile Duct Diseases; Chemical and Drug Induced Liver Injury; Chickenpox; Child; Child, Preschool; Cyt | 1985 |
Liver injury model in mice for immunopharmacological study.
Topics: Animals; Antibodies; Antibodies, Bacterial; Chemical and Drug Induced Liver Injury; Cyclophosphamide | 1988 |
Severe hepatic failure after ARA-A-prednisolone for chronic type B hepatitis.
Topics: Adult; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Hepatitis B; Humans; Male; | 1987 |
Nephrotic syndrome associated with hyper-high-density lipoproteinemia potentiated by prednisolone therapy.
Topics: Adult; Apolipoprotein A-I; Apolipoproteins A; Chemical and Drug Induced Liver Injury; Cholesterol, H | 1985 |
[Genesis of atraumatic liver hemorrhages].
Topics: Animals; Chemical and Drug Induced Liver Injury; Diagnosis, Differential; Fatty Liver; Female; Hemor | 1985 |
[A case of autoimmune hemolytic anemia, interstitial pneumonia and liver injury occurred during one month's medication of small dose of alpha-methyldopa].
Topics: Aged; Anemia, Hemolytic, Autoimmune; Chemical and Drug Induced Liver Injury; Humans; Male; Methyldop | 1985 |
Management of chronic hepatitis.
Topics: Azathioprine; Chemical and Drug Induced Liver Injury; Chronic Disease; Female; Hepatitis; Hepatitis | 1971 |
Rifampicin hepatitis. A clinical and histological study.
Topics: Adult; Aged; Alcoholism; Biopsy; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; | 1974 |
Clinical use of corticosteroid and immunosuppressive drugs in liver disease.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Azathioprine; Biliary Tract Diseases; Chemical and D | 1974 |
Side effects of rifampicin. A clinical study.
Topics: Acute Disease; Acute Kidney Injury; Adult; Ambulatory Care; Amylases; Chemical and Drug Induced Live | 1973 |
Gross paracetamol overdosage with recovery.
Topics: Acetaminophen; Adult; Bilirubin; Chemical and Drug Induced Liver Injury; Humans; Male; Necrosis; Pre | 1973 |
[Agranulocytosis and cholestatic hepatitis occurring during tetran therapy].
Topics: Agranulocytosis; Chemical and Drug Induced Liver Injury; Cholestasis; Drug Hypersensitivity; Female; | 1974 |
[Chloramphenicol panmyelopathy in a child].
Topics: Anabolic Agents; Blood Cell Count; Blood Transfusion; Bone Marrow; Bone Marrow Diseases; Bone Marrow | 1970 |
Acute miliary necrosis resembling peliosis hepatitis produced by the combination of glucocorticoid and gadolinium chloride.
Topics: Animals; Chemical and Drug Induced Liver Injury; Chlorides; Disease Models, Animal; Female; Gadolini | 1972 |
The effect of prednisolone and other factors on the catabolism of 5-fluorouracil in rats.
Topics: Animals; Autoradiography; Carbon Dioxide; Carbon Isotopes; Carbon Tetrachloride Poisoning; Chemical | 1971 |
[Febrile toxic hepatitis with eosinophilia, lymphadenopathy and exanthema during phenytoin therapy].
Topics: Adult; Chemical and Drug Induced Liver Injury; Eosinophilia; Exanthema; Fever; Humans; Liver Functio | 1971 |
[Reversibility of experimental amyloidosis].
Topics: Adrenal Cortex Hormones; Amyloidosis; Animals; Caseins; Chemical and Drug Induced Liver Injury; Dexa | 1971 |
[The effect of various anti-inflammatory preparations on phagocytosis in experimental hepatitis].
Topics: Animals; Anti-Inflammatory Agents; Carbon Tetrachloride Poisoning; Chemical and Drug Induced Liver I | 1969 |
The unique distribution of ornithine aminotransferase in rat liver mitochondria.
Topics: Aflatoxins; Animals; Ascitic Fluid; Carbon Tetrachloride Poisoning; Carcinoma, Ehrlich Tumor; Centri | 1970 |
Sensitivity of liver function test.
Topics: Animals; Chemical and Drug Induced Liver Injury; Liver Diseases; Liver Function Tests; Prednisolone; | 1970 |
[Ultrastructure of liver injuries in the rat produced by the administration of a single dose of prednisolone].
Topics: Animals; Body Weight; Chemical and Drug Induced Liver Injury; Liver Diseases; Microscopy, Electron; | 1970 |
Alcoholic hepatitis.
Topics: Alcoholism; Chemical and Drug Induced Liver Injury; Humans; Liver Cirrhosis; Prednisolone | 1971 |
Prednisolone-induced hepatic injury. Ultrastructural and biochemical changes in rabbits.
Topics: Alkaline Phosphatase; Animals; Aspartate Aminotransferases; Bile Ducts, Intrahepatic; Chemical and D | 1971 |
[Jaundice after ovulation inhibiting steroids].
Topics: Adult; Biopsy; Chemical and Drug Induced Liver Injury; Cholestasis; Contraceptives, Oral; Ethinyl Es | 1969 |